NMR spectroscopy is an emerging analytical tool for measuring complex drug product qualities, e.g., protein higher order structure (HOS) or heparin chemical composition. Most drug NMR spectra have been visually analyzed; however, NMR spectra are inherently quantitative and multivariate and thus suitable for chemometric analysis. Therefore, quantitative measurements derived from chemometric comparisons between spectra could be a key step in establishing acceptance criteria for a new generic drug or a new batch after manufacture change. To measure the capability of chemometric methods to differentiate comparator NMR spectra, we calculated inter-spectra difference metrics on 1D/2D spectra of two insulin drugs, Humulin R® and Novolin R®, from different manufacturers. Both insulin drugs have an identical drug substance but differ in formulation. Chemometric methods (i.e., principal component analysis (PCA), 3-way Tucker3 or graph invariant (GI)) were performed to calculate Mahalanobis distance (DM) between the two brands (inter-brand) and distance ratio (DR) among the different lots (intra-brand). The PCA on 1D inter-brand spectral comparison yielded a DM value of 213. In comparing 2D spectra, the Tucker3 analysis yielded the highest differentiability value (DM = 305) in the comparisons made followed by PCA (DM = 255) then the GI method (DM = 40). In conclusion, drug quality comparisons among different lots might benefit from PCA on 1D spectra for rapidly comparing many samples, while higher resolution but more time-consuming 2D-NMR-data-based comparisons using Tucker3 analysis or PCA provide a greater level of assurance for drug structural similarity evaluation between drug brands.
Mahalanobis distance distance ratio PCA Tucker3 graph invariant
This is a preview of subscription content, log in to check access.
We thank the reviewer for pointing us to the Tucker3 method. We thank Prof. P.M. Kroonenberg for helpful discussion on Tucker3 application.
Support for this work from the US FDA CDER Critical Path Award is gratefully acknowledged.
Compliance with Ethical Standards
This article reflects the views of the author and should not be construed to represent U.S. FDA’s views or policies.
ESM 1NMR data processing scripts, MATLAB scripts, R scripts and principle component scores can be found in supplementary materials. (DOCX 523 kb)
Zuperl S, Pristovsek P, Menart V, Gaberc-Porekar V, Novic M. Chemometric approach in quantification of structural identity/similarity of proteins in biopharmaceuticals. J Chem Inf Model. 2007;47(3):737–43.CrossRefPubMedGoogle Scholar
Poppe L, Jordan JB, Rogers G, Schnier PD. On the analytical superiority of 1D NMR for fingerprinting the higher order structure of protein therapeutics compared to multidimensional NMR methods. Anal Chem. 2015;87:5539–45.CrossRefPubMedGoogle Scholar
Poppe L, Jordan JB, Lawson K, Jerums M, Apostol I, Schnier PD. Profiling formulated monoclonal antibodies by H-1 NMR spectroscopy. Anal Chem. 2013;85(20):9623–9.CrossRefPubMedGoogle Scholar
Guerrini M, Rudd TR, Mauri L, Macchi E, Fareed J, Yates EA, et al. Differentiation of generic Enoxaparins marketed in the United States by employing NMR and multivariate analysis. Anal Chem. 2015;87(16):8275–83.CrossRefPubMedGoogle Scholar
Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the nation's biosimilars program. New Engl J Med. 2011;365(5):385–8.CrossRefPubMedGoogle Scholar
Ghasriani H, Hodgson DJ, Brinson RG, McEwen I, Buhse LF, Kozlowski S, et al. Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars. Nat Biotechnol. 2016;34(2):139–41.CrossRefPubMedCentralPubMedGoogle Scholar
Keire DA, Buhse LF, Al-Hakim A. Characterization of currently marketed heparin products: composition analysis by 2D-NMR. Anal Methods-Uk. 2013;5(12):2984–94.CrossRefGoogle Scholar
Ye HP, Toby TK, Sommers CD, Ghasriani H, Trehy ML, Ye W, et al. Characterization of currently marketed heparin products: key tests for LMWH quality assurance. J Pharmaceut Biomed. 2013;85:99–107.CrossRefGoogle Scholar
Rogstad S, Pang E, Sommers C, Hu M, Jiang XH, Keire DA, et al. Modern analytics for synthetically derived complex drug substances: NMR, AFFF-MALS, and MS tests for glatiramer acetate. Anal Bioanal Chem. 2015;407(29):8647–59.CrossRefPubMedGoogle Scholar
Levy MJ, Boyneii MT, Rogstad S, Skanchy DJ, Jiang XH, Geerlof-Vidavsky I. Marketplace analysis of conjugated estrogens: determining the consistently present steroidal content with LC-MS. AAPS J. 2015;17(6):1438–45.CrossRefPubMedCentralPubMedGoogle Scholar
Arzhantsev S, Vilker V, Kauffman J. Deep-ultraviolet (UV) resonance Raman spectroscopy as a tool for quality control of formulated therapeutic proteins. Appl Spectrosc. 2012;66(11):1262–8.CrossRefPubMedGoogle Scholar
Hmiel LK, Brorson KA, Boyne MT. Post-translational structural modifications of immunoglobulin G and their effect on biological activity. Anal Bioanal Chem. 2015;407(1):79–94.CrossRefPubMedGoogle Scholar
Korang-Yeboah M, Rahman Z, Shah D, Mohammad A, Wu SY, Siddiqui A, et al. Impact of formulation and process variables on solid-state stability of theophylline in controlled release formulations. Int J Pharm. 2016;499(1–2):20–8.CrossRefPubMedGoogle Scholar
Panjwani N, Hodgson DJ, Sauve S, Aubin Y. Assessment of the effects of pH, formulation and deformulation on the conformation of interferon alpha-2 by NMR. J Pharm Sci-Us. 2010;99(8):3334–42.CrossRefGoogle Scholar
Jin X, Kang S, Kwon H, Park S, Heteronuclear NMR. As a 4-in-1 analytical platform for detecting modification-specific signatures of therapeutic insulin formulations. Anal Chem. 2014;86(4):2050–6.CrossRefPubMedGoogle Scholar
Aubin Y, Jones C, Freedberg DI. Using NMR spectroscopy to obtain the higher order structure of biopharmaceutical products. Biopharm Int. 2010;Supplement:28–34.Google Scholar
Aubin Y, Hodgson DJ, Thach WB, Gingras G, Sauve S. Monitoring effects of excipients, formulation parameters and mutations on the high order structure of filgrastim by NMR. Pharm Res. 2015;32:3365–75.CrossRefPubMedGoogle Scholar
Aubin Y, Gingras G, Sauve S. Assessment of the three-dimensional structure of recombinant protein therapeutics by NMR fingerprinting: demonstration on recombinant human granulocyte macrophage-colony stimulation factor. Anal Chem. 2008;80(7):2623–7.CrossRefPubMedGoogle Scholar
Amezcua CA, Szabo CM. Assessment of higher order structure comparability in therapeutic proteins using nuclear magnetic resonance spectroscopy. J Pharm Sci-Us. 2013;102(6):1724–33.CrossRefGoogle Scholar
Chen K, Long DS, Lute SC, Levy MJ, Brorson KA, Keire DA. Simple NMR methods for evaluating higher order structures of monoclonal antibody therapeutics with quinary structure. J Pharmaceut Biomed. 2016;128:398–407.CrossRefGoogle Scholar
Zang QD, Keire DA, Buhse LF, Wood RD, Mital DP, Haque S, et al. Identification of heparin samples that contain impurities or contaminants by chemometric pattern recognition analysis of proton NMR spectral data. Anal Bioanal Chem. 2011;401(3):939–55.CrossRefPubMedGoogle Scholar
Kiers HAL. Towards a standardized notation and terminology in multiway analysis. J Chemom. 2000;14(3):105–22.CrossRefGoogle Scholar
Kroonenberg PM, Basford KE, Gemperline PJ. Grouping three-mode data with mixture methods: the case of the diseased blue crabs. J Chemom. 2004;18(11):508–18.CrossRefGoogle Scholar
Keller D, Clausen R, Josefsen K, Led JJ. Flexibility and bioactivity of insulin: an NMR investigation of the solution structure and folding of an unusually flexible human insulin mutant with increased biological activity. Biochemistry. 2001;40(35):10732–40.CrossRefPubMedGoogle Scholar
Chang XQ, Jorgensen AMM, Bardrum P, Led JJ. Solution structures of the R-6 human insulin hexamer. Biochemistry. 1997;36(31):9409–22.CrossRefPubMedGoogle Scholar
Dyrby M, Baunsgaard D, Bro R, Engelsen SB. Multiway chemometric analysis of the metabolic response to toxins monitored by NMR. Chemometr Intell Lab. 2005;76(1):79–89.CrossRefGoogle Scholar
Pedersen HT, Bro R, Engelsen SB. Towards rapid and unique curve resolution of low-field NMR relaxation data: trilinear SLICING versus two-dimensional curve fitting. J Magn Reson. 2002;157(1):141–55.CrossRefPubMedGoogle Scholar
Randic M. A graph theoretical characterization of proteomics maps. Int J Quantum Chem. 2002;90(2):848–58.CrossRefGoogle Scholar